Abstract
Vasoactive intestinal peptide (VIP) mediates important events during the development of the nervous system. VIP can stimulate neuronogenesis as well as differentiation and neurite outgrowth; it can promote the survival of neurons and assist in neuronal repair; it is also anti-inflammatory and can modulate immune responses. In addition, VIP is necessary for the normal growth and development of the early postimplantation mouse embryo during the period when the major embryonic events are neural tube formation, neuronogenesis and expansion of the vascular system. Receptors for VIP appear during early postimplantation embryogenesis in the rodent and exhibit changing localization patterns throughout the development of the brain. During embryogenesis, unregulated VIP may have major and permanent consequences on the formation of the brain and may be a participating factor in disorders of neurodevelopment. VIP has been linked to autism, Down syndrome and fetal alcohol syndrome. This paper will review the role of VIP in neurodevelopment, its known involvement in neurodevelopmental disorders and propose ways in which VIP might be of therapeutic value.
Keywords: Embryogenesis, Autism, Down syndrome, Fetal alcohol syndrome
Current Pharmaceutical Design
Title: Vasoactive Intestinal Peptide in Neurodevelopmental Disorders:Therapeutic Potential
Volume: 13 Issue: 11
Author(s): Joanna M. Hill
Affiliation:
Keywords: Embryogenesis, Autism, Down syndrome, Fetal alcohol syndrome
Abstract: Vasoactive intestinal peptide (VIP) mediates important events during the development of the nervous system. VIP can stimulate neuronogenesis as well as differentiation and neurite outgrowth; it can promote the survival of neurons and assist in neuronal repair; it is also anti-inflammatory and can modulate immune responses. In addition, VIP is necessary for the normal growth and development of the early postimplantation mouse embryo during the period when the major embryonic events are neural tube formation, neuronogenesis and expansion of the vascular system. Receptors for VIP appear during early postimplantation embryogenesis in the rodent and exhibit changing localization patterns throughout the development of the brain. During embryogenesis, unregulated VIP may have major and permanent consequences on the formation of the brain and may be a participating factor in disorders of neurodevelopment. VIP has been linked to autism, Down syndrome and fetal alcohol syndrome. This paper will review the role of VIP in neurodevelopment, its known involvement in neurodevelopmental disorders and propose ways in which VIP might be of therapeutic value.
Export Options
About this article
Cite this article as:
Hill M. Joanna, Vasoactive Intestinal Peptide in Neurodevelopmental Disorders:Therapeutic Potential, Current Pharmaceutical Design 2007; 13 (11) . https://dx.doi.org/10.2174/138161207780618975
DOI https://dx.doi.org/10.2174/138161207780618975 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Expanding Spectrum of Sodium Potassium Chloride Co-transporters in the Pathophysiology of Diseases
Current Neuropharmacology Infective Proteins: The Prion Puzzle
Current Protein & Peptide Science subject Index To Volume 2
Current Molecular Medicine Hepatocarcinogenesis and Ceramide/Cholesterol Metabolism
Anti-Cancer Agents in Medicinal Chemistry Epigenetic Modulation Using Small Molecules - Targeting Histone Acetyltransferases in Disease
Current Medicinal Chemistry Regulation of Transcription Factors by Heterotrimeric G Proteins
Current Molecular Pharmacology Targeting ADAM17 Sheddase Activity in Cancer
Current Drug Targets Immunotherapy of Human Cancers Using Gene Modified T Lymphocytes
Current Gene Therapy Prolyl Oligopeptidase: A Rising Star on the Stage of Neuroinflammation Research
CNS & Neurological Disorders - Drug Targets Exploring Mechanisms of MicroRNA Downregulation in Cancer
MicroRNA NAD Biosynthesis in Humans - Enzymes, Metabolites and Therapeutic Aspects
Current Topics in Medicinal Chemistry The Effects of Locus Coeruleus and Norepinephrine in Methamphetamine Toxicity
Current Neuropharmacology Benzofuran Small Molecules as Potential Inhibitors of Human Protein Kinases. A Review
Current Pharmaceutical Design Therapeutic Potential of Plant Extracts and Phytochemicals Against Brain Ischemia-Reperfusion Injury: A Review
The Natural Products Journal Historical Spice as a Future Drug: Therapeutic Potential of Piperlongumine
Current Pharmaceutical Design Aptamers as Targeting Delivery Devices or Anti-cancer Drugs for Fighting Tumors
Current Drug Metabolism A Fluorescent Alkyllysophospholipid Analog Exhibits Selective Cytotoxicity Against the Hormone-Insensitive Prostate Cancer Cell Line PC3
Anti-Cancer Agents in Medicinal Chemistry Clearance of Amyloid-β Peptide by Neuronal and Non-Neuronal Cells: Proteolytic Degradation by Secreted and Membrane associated Proteases
Current Neurovascular Research Can Diet and Physical Activity Limit Alzheimer's Disease Risk?
Current Alzheimer Research Neuroprotective Role of Nanoparticles Against Alzheimer's Disease
Current Drug Metabolism